| Similar Articles |
|---|
 |
The Motley Fool
August 3, 2006
S.J. Caplan |
AstraZeneca's Path to Avoid Pain The pharmaceutical giant partners with Pozen to co-develop a drug. Take heart, AstraZeneca shareholders! No queasy stomachs are expected in your future.   |
The Motley Fool
December 4, 2008
Brian Orelli |
Poor Pozen It's not often that you see a drug developer release data from two positive phase 3 trials for its lead pipeline compound and see its shares fall more than 4%, but that's what happened to Pozen. |
The Motley Fool
June 2, 2004
Roger Nusbaum |
POZEN Is a Poser Here's a great example of the riskiest type of biotech stock. |
The Motley Fool
August 3, 2007
Brian Orelli |
Another Headache for Pozen Investors Drugmaker Pozen might have to run one more trial for the FDA for its migraine drug. |
The Motley Fool
November 26, 2011
Stephanie Baum |
Pozen Inks $75 Million Royalty Deal for Treximet The pharma sells U.S. rights for the migraine drug to Canada's national pension fund. |
The Motley Fool
May 3, 2010
Brian Orelli |
While You Were Reveling in Dendreon's Win The FDA has approved Vimovo, an arthritis drug from Pozen and AstraZeneca, and Bristol-Myers Squibb also got a decision from the FDA, but it wasn't the positive kind. |
The Motley Fool
May 17, 2007
Mike Havrilla |
Pozen Poised for Profits The pharmaceutical reported first-quarter results. But investors should look to buy shares of this company because of how its results may look later this year. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
The Motley Fool
January 8, 2010
Brian Orelli |
Heartburn Relieved ... for Now AstraZeneca settles its patent dispute with Teva. |
The Motley Fool
July 17, 2007
Andrew R. Vaino |
Problems Posed for Pozen If its latest drug isn't approved, the pharmaceutical's stock will clearly tank. Any benefits stemming from the drug's successful approval are harder to gauge. |
The Motley Fool
August 17, 2007
Brian Orelli |
Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully. |
The Motley Fool
July 30, 2010
Cliff D'Arcy |
Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline. |
The Motley Fool
April 16, 2011 |
Pozen Wins Injunction Blocking Generic Migraine Drug The ruling against Par Pharmaceutical comes just in time for Pozen. |
The Motley Fool
February 29, 2008
Brian Orelli |
Merck's Complicated Partnerships Merck has decided to continue its complicated partnership with AstraZeneca for at least a few more years. |
The Motley Fool
December 28, 2005
Stephen D. Simpson |
AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either. |
The Motley Fool
October 26, 2006
Brian Lawler |
Market Rejects AstraZeneca's Remedy Investors pummel the pharmaceutical firm, despite its impressive results. |
The Motley Fool
February 24, 2011
Brian Orelli |
Youth in Revolt Against POZEN POZEN fails to get a pediatric extension on its migraine drug. |
The Motley Fool
May 21, 2009
Robert Steyer |
The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations? |
